Target Information

Target General Information

Top

Target ID

T59328 (Former ID: TTDS00355)

Target Name

Epidermal growth factor receptor (EGFR)

Synonyms

Receptor tyrosine-protein kinase erbB-1; Proto-oncogene c-ErbB-1; HER1; ERBB1; ERBB

Click to Show/Hide

Gene Name

EGFR

Target Type

Successful target

[1]

Disease

[+] 10 Target-related Diseases

Angina pectoris [ICD-11: BA40]

Breast cancer [ICD-11: 2C60-2C6Y]

Colorectal cancer [ICD-11: 2B91]

Diabetic foot ulcer [ICD-11: BD54]

Ischemia [ICD-11: 8B10-8B11]

Lung cancer [ICD-11: 2C25]

Non-small-cell lung cancer [ICD-11: 2C25]

Renal cell carcinoma [ICD-11: 2C90]

Solid tumour/cancer [ICD-11: 2A00-2F9Z]

Unspecific body region injury [ICD-11: ND56]

Function

Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Plays a role in enhancing learning and memory performance (By similarity).

Click to Show/Hide

BioChemical Class

Kinase

UniProt ID

EGFR_HUMAN

EC Number

EC 2.7.10.1

Sequence

MRPSGTAGAALLALLAALCPASRALEEKKVCQGTSNKLTQLGTFEDHFLSLQRMFNNCEV
VLGNLEITYVQRNYDLSFLKTIQEVAGYVLIALNTVERIPLENLQIIRGNMYYENSYALA
VLSNYDANKTGLKELPMRNLQEILHGAVRFSNNPALCNVESIQWRDIVSSDFLSNMSMDF
QNHLGSCQKCDPSCPNGSCWGAGEENCQKLTKIICAQQCSGRCRGKSPSDCCHNQCAAGC
TGPRESDCLVCRKFRDEATCKDTCPPLMLYNPTTYQMDVNPEGKYSFGATCVKKCPRNYV
VTDHGSCVRACGADSYEMEEDGVRKCKKCEGPCRKVCNGIGIGEFKDSLSINATNIKHFK
NCTSISGDLHILPVAFRGDSFTHTPPLDPQELDILKTVKEITGFLLIQAWPENRTDLHAF
ENLEIIRGRTKQHGQFSLAVVSLNITSLGLRSLKEISDGDVIISGNKNLCYANTINWKKL
FGTSGQKTKIISNRGENSCKATGQVCHALCSPEGCWGPEPRDCVSCRNVSRGRECVDKCN
LLEGEPREFVENSECIQCHPECLPQAMNITCTGRGPDNCIQCAHYIDGPHCVKTCPAGVM
GENNTLVWKYADAGHVCHLCHPNCTYGCTGPGLEGCPTNGPKIPSIATGMVGALLLLLVV
ALGIGLFMRRRHIVRKRTLRRLLQERELVEPLTPSGEAPNQALLRILKETEFKKIKVLGS
GAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGI
CLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAA
RNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSY
GVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPK
FRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQ
QGFFSSPSTSRTPLLSSLSATSNNSTVACIDRNGLQSCPIKEDSFLQRYSSDPTGALTED
SIDDTFLPVPEYINQSVPKRPAGSVQNPVYHNQPLNPAPSRDPHYQDPHSTAVGNPEYLN
TVQPTCVNSTFDSPAHWAQKGSHQISLDNPDYQQDFFPKEAKPNGIFKGSTAENAEYLRV
APQSSEFIGA

Click to Show/Hide

3D Structure

Click to Show 3D Structure of This Target

AlphaFold

ADReCS ID

BADD_A00924 ; BADD_A01146 ; BADD_A01626 ; BADD_A02005 ; BADD_A05675 ; BADD_A06535

HIT2.0 ID

T43N2D

Drugs and Modes of Action

Top

Approved Drug(s)

[+] 16 Approved Drugs

BIBW 2992

Drug Info

Approved

Non-small-cell lung cancer

[6], [7]

Cetuximab

Drug Info

Approved

Colorectal cancer

[8], [9]

Dacomitinib

Drug Info

Approved

Non-small-cell lung cancer

[10]

Epidermal growth factor

Drug Info

Approved

Vulnerary

[11]

Erlotinib

Drug Info

Approved

Non-small-cell lung cancer

[9], [12]

Gefitinib

Drug Info

Approved

Solid tumour/cancer

[13], [14]

HEGF

Drug Info

Approved

Diabetic foot ulcer

[15]

Lapatinib

Drug Info

Approved

Breast cancer

[16], [17]

Necitumumab

Drug Info

Approved

Colorectal cancer

[18], [19]

NERATINIB MALEATE

Drug Info

Approved

HER2/NEU overexpressing breast cancer

[20]

Nitroglycerin

Drug Info

Approved

Diabetic foot ulcer

[15]

Osimertinib

Drug Info

Approved

Non-small-cell lung cancer

[21]

Panitumumab

Drug Info

Approved

Colorectal cancer

[22], [23]

SKI-758

Drug Info

Approved

Ischemia

[11], [24]

Vandetanib

Drug Info

Approved

Solid tumour/cancer

[25], [26]

Icotinib hydrochloride

Drug Info

Registered

Non-small-cell lung cancer

[27], [28], [29]

Clinical Trial Drug(s)

[+] 44 Clinical Trial Drugs

Bevacizumab + Erlotinib

Drug Info

Phase 3

Metastatic colorectal cancer

[33], [34]

CO-1686

Drug Info

Phase 3

Lung cancer

[35]

DE-766

Drug Info

Phase 3

Non-small-cell lung cancer

[36], [37]

EGF816

Drug Info

Phase 3

Non-small-cell lung cancer

[38]

HKI-272

Drug Info

Phase 3

Breast cancer

[39], [38]

Rindopepimut

Drug Info

Phase 3

Glioblastoma multiforme

[40]

SYM-004

Drug Info

Phase 3

Metastatic colorectal cancer

[38]

Zalutumumab

Drug Info

Phase 3

Head and neck cancer

[41]

Indium-111

Drug Info

Phase 2/3

Solid tumour/cancer

[42]

Varlitinib

Drug Info

Phase 2/3

Metastatic biliary tract neoplasms

[38]

ABT-414

Drug Info

Phase 2

Glioblastoma multiforme

[48], [49]

ASP8273

Drug Info

Phase 2

Non-small-cell lung cancer

[50]

BMS-690514

Drug Info

Phase 2

Chronic pain

[51]

CetuGEX

Drug Info

Phase 2

Solid tumour/cancer

[52]

Depatuxizumab

Drug Info

Phase 2

Glioblastoma of brain

[53]

HER1-VSSP vaccine

Drug Info

Phase 2

Solid tumour/cancer

[54], [55]

HM-78136B

Drug Info

Phase 2

Solid tumour/cancer

[56], [57]

Matuzumab

Drug Info

Phase 2

Gastric adenocarcinoma

[58]

MEHD-7945A

Drug Info

Phase 2

Colorectal cancer

[59], [60]

Pazopanib + Tyverb/Tykerb

Drug Info

Phase 2

Inflammatory breast cancer

[61]

Pelitinib

Drug Info

Phase 2

Lymphoma

[62], [63]

RM-1929

Drug Info

Phase 2

Head and neck cancer

[38], [64]

TT-100

Drug Info

Phase 2

Non-small-cell lung cancer

[65]

VATALANIB

Drug Info

Phase 2

Solid tumour/cancer

[66], [67]

CART-EGFR

Drug Info

Phase 1/2

Solid tumour/cancer

[73]

EGFR CART

Drug Info

Phase 1/2

Colorectal cancer

[74]

EMD 55900

Drug Info

Phase 1/2

Glioma

[75]

SN-32793

Drug Info

Phase 1/2

Non-small-cell lung cancer

[76]

Sym013

Drug Info

Phase 1/2

Epithelial ovarian cancer

[38]

Sym015

Drug Info

Phase 1/2

Solid tumour/cancer

[64], [38]

AMG 595

Drug Info

Phase 1

Glioblastoma multiforme

[87]

Anti-EGFR CAR T

Drug Info

Phase 1

Glioma

[88]

Anti-HER3/EGFR DAF

Drug Info

Phase 1

Metastatic epithelial tumour

[89]

AST-1306

Drug Info

Phase 1

Solid tumour/cancer

[90]

BIBX-1382

Drug Info

Phase 1

Chronic lymphocytic leukaemia

[91], [92]

Cipatinib

Drug Info

Phase 1

Solid tumour/cancer

[93]

EGFR806-specific CAR T cell

Drug Info

Phase 1

Atypical teratoid/rhabdoid tumour

[94]

HER-2/HER-1 vaccine

Drug Info

Phase 1

Solid tumour/cancer

[95]

IMGN289

Drug Info

Phase 1

Solid tumour/cancer

[96]

LY3164530

Drug Info

Phase 1

Advanced cancer

[97]

MM-151

Drug Info

Phase 1

Solid tumour/cancer

[98]

MR1-1

Drug Info

Phase 1

Brain cancer

[99]

PF-05230907

Drug Info

Phase 1

Nontraumatic intracerebral hemorrhage

[100]

SYN004

Drug Info

Phase 1

Solid tumour/cancer

[64], [38]

Discontinued Drug(s)

[+] 7 Discontinued Drugs

PKI166

Drug Info

Discontinued in Phase 2

Esophageal cancer

[101], [102]

RG7160

Drug Info

Discontinued in Phase 2

Metastatic colorectal cancer

[103]

AZD4769

Drug Info

Discontinued in Phase 1

Solid tumour/cancer

[104]

PD-153035

Drug Info

Discontinued in Phase 1

Psoriasis vulgaris

[105]

TAK165

Drug Info

Discontinued in Phase 1

Solid tumour/cancer

[106], [107]

CGP-52411

Drug Info

Terminated

Solid tumour/cancer

[112]

Heparin-EGF-like factor

Drug Info

Terminated

Gastrointestinal disease

[113], [114]

Preclinical Drug(s)

[+] 1 Preclinical Drugs

EGFR/IGFR tandem adnectin

Drug Info

Preclinical

Solid tumour/cancer

[110]

Mode of Action

[+] 6 Modes of Action

Inhibitor

[+] 98 Inhibitor drugs

BIBW 2992

Drug Info

[115]

Erlotinib

Drug Info

[119]

Gefitinib

Drug Info

[120], [121]

Lapatinib

Drug Info

[122], [123]

Osimertinib

Drug Info

[125]

SKI-758

Drug Info

[127]

Vandetanib

Drug Info

[128], [129]

Bevacizumab + Erlotinib

Drug Info

[131]

EGF816

Drug Info

[133]

HKI-272

Drug Info

[134]

ASP8273

Drug Info

[140]

BMS-690514

Drug Info

[141]

HM-78136B

Drug Info

[38], [142]

Pazopanib + Tyverb/Tykerb

Drug Info

[145]

TT-100

Drug Info

[147]

VATALANIB

Drug Info

[134]

SN-32793

Drug Info

[118]

IMGN289

Drug Info

[154]

PF-05230907

Drug Info

[156]

SYN004

Drug Info

[64]

AZD4769

Drug Info

[129]

TAK165

Drug Info

[128]

EGFR/IGFR tandem adnectin

Drug Info

[160]

CGP-52411

Drug Info

[161]

CGP-53353

Drug Info

[162]

(3-Bromo-phenyl)-quinazolin-4-yl-amine

Drug Info

[163]

(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin

Drug Info

[164]

(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate

Drug Info

[165]

2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile

Drug Info

[166]

2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile

Drug Info

[166]

2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile

Drug Info

[165]

2-cyano-3-(3,4-dihydroxyphenyl)acrylamide

Drug Info

[165]

2-methoxy-4-(2-nitrovinyl)phenol

Drug Info

[165]

3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione

Drug Info

[167]

3,4-diphenyl-1H-pyrrole-2,5-dione

Drug Info

[167]

3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one

Drug Info

[168]

3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione

Drug Info

[167]

3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione

Drug Info

[167]

3-Pyridin-4-yl-quinoline-6,7-diol

Drug Info

[169]

4-(2-nitroprop-1-enyl)benzene-1,2-diol

Drug Info

[165]

4-(2-nitrovinyl)benzene-1,2-diol

Drug Info

[165]

4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline

Drug Info

[170]

4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline

Drug Info

[170]

4-(3-Bromo-phenylamino)-quinazoline-6,7-diol

Drug Info

[163]

4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid

Drug Info

[165]

4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline

Drug Info

[171]

4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline

Drug Info

[172]

5,6-Bis-p-tolylamino-isoindole-1,3-dione

Drug Info

[162]

5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide

Drug Info

[173]

6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline

Drug Info

[172]

6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline

Drug Info

[172]

6,7-diethoxy-4-styrylquinazoline

Drug Info

[172]

6,7-dimethoxy-4-(2-phenylethynyl)quinazoline

Drug Info

[172]

6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline

Drug Info

[172]

6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline

Drug Info

[172]

6,7-dimethoxy-N-m-tolylquinazolin-4-amine

Drug Info

[174]

6-chloro-N-(3-chlorophenyl)quinazolin-4-amine

Drug Info

[175]

AG 112

Drug Info

[176]

AG 9

Drug Info

[176]

AG-213

Drug Info

[171]

AG-538

Drug Info

[165]

Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine

Drug Info

[163]

Benzyl-quinazolin-4-yl-amine

Drug Info

[177]

CL-387785

Drug Info

[174]

EGFR inhibitor

Drug Info

[178]

Epitinib

Drug Info

[118]

HDS-029

Drug Info

[179]

HKI-9924129

Drug Info

[180]

HM-61713B

Drug Info

[118]

HTS-00213

Drug Info

[174]

HTS-02876

Drug Info

[174]

HTS-05058

Drug Info

[178]

LAVENDUSTIN A

Drug Info

[181]

MT-062

Drug Info

[118]

N*4*-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine

Drug Info

[163]

N*4*-(3-Bromo-phenyl)-quinazoline-4,6-diamine

Drug Info

[183]

N*4*-(3-Bromo-phenyl)-quinazoline-4,7-diamine

Drug Info

[177]

N*4*-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine

Drug Info

[184]

N-(4-(phenylamino)quinazolin-6-yl)acrylamide

Drug Info

[185]

N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide

Drug Info

[186]

N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide

Drug Info

[186]

N4-(3-chlorophenyl)quinazoline-4,6-diamine

Drug Info

[187]

ON-128

Drug Info

[118]

OSI-75

Drug Info

[188]

PD-0166326

Drug Info

[180]

PD-0173956

Drug Info

[180]

PD-158780

Drug Info

[184]

PD-168393

Drug Info

[185]

PD182905

Drug Info

[189]

PMID24915291C38

Drug Info

[191]

PMID8568816C56

Drug Info

[192]

PP121

Drug Info

[193]

RG-50810

Drug Info

[165]

RM-6427

Drug Info

[118]

Ro-4396686

Drug Info

[194]

Theliatinib

Drug Info

[118]

WHI-P154

Drug Info

[195]

WZ-3146

Drug Info

[118]

Antagonist

[+] 11 Antagonist drugs

Dacomitinib

Drug Info

[118]

NERATINIB MALEATE

Drug Info

[20]

Icotinib hydrochloride

Drug Info

[130]

Depatuxizumab

Drug Info

[64]

RM-1929

Drug Info

[38]

Sym013

Drug Info

[64], [38]

Sym015

Drug Info

[64]

BIBX-1382

Drug Info

[153]

MM-151

Drug Info

[64]

EDP-13

Drug Info

[118]

IPS-01003

Drug Info

[118]

Modulator

[+] 25 Modulator drugs

Epidermal growth factor

Drug Info

[118]

Necitumumab

Drug Info

[124]

CO-1686

Drug Info

[132]

DE-766

Drug Info

[118]

Rindopepimut

Drug Info

[124]

Varlitinib

Drug Info

[137]

MEHD-7945A

Drug Info

[137], [144]

Pelitinib

Drug Info

[146]

AMG 595

Drug Info

[148]

Anti-HER3/EGFR DAF

Drug Info

[149]

AST-1306

Drug Info

[150], [151], [152]

Cipatinib

Drug Info

[137]

LY3164530

Drug Info

[144]

MR1-1

Drug Info

[155]

PKI166

Drug Info

[157]

RG7160

Drug Info

[158]

PD-153035

Drug Info

[159]

Heparin-EGF-like factor

Drug Info

[113], [114]

AGT-2000

Drug Info

[118]

AL-6802

Drug Info

[118]

LA22-radioimmunoconjugates

Drug Info

[118]

MG-111

Drug Info

[182]

PF 5208766

Drug Info

[190]

SYM-011

Drug Info

[118]

TGF alpha

Drug Info

[118]

Activator

[+] 2 Activator drugs

HEGF

Drug Info

[15]

Nitroglycerin

Drug Info

[15]

Suppressor

[+] 1 Suppressor drugs

Panitumumab

Drug Info

[126]

CAR-T-Cell-Therapy

[+] 4 CAR-T-Cell-Therapy drugs

CART-EGFR

Drug Info

[73]

EGFR CART

Drug Info

[74]

Anti-EGFR CAR T

Drug Info

[88]

EGFR806-specific CAR T cell

Drug Info

[94]

Cell-based Target Expression Variations

Top

Cell-based Target Expression Variations

Cell-based Target Expression Variations Info

Drug Binding Sites of Target

Top

Ligand Name: Lapatinib

Ligand Info

Structure Description

EGFR kinase domain complexed with a quinazoline inhibitor- GW572016

PDB:1XKK

Method

X-ray diffraction

Resolution

2.40 Å

Mutation

[196]

PDB Sequence

ALLRILKETE

⁷¹¹

FKKIKVLGSG

⁷²¹

AFGTVYKGLW

⁷³¹

IPVKIPVAIK

⁷⁴⁵

ELREKANKEI

⁷⁵⁹

LDEAYVMASV

⁷⁶⁹

DNPHVCRLLG

⁷⁷⁹

ICLTSTVQLI

⁷⁸⁹

TQLMPFGCLL

⁷⁹⁹

DYVREHKDNI

⁸⁰⁹

GSQYLLNWCV

⁸¹⁹

QIAKGMNYLE

⁸²⁹

DRRLVHRDLA

⁸³⁹

ARNVLVKTPQ

⁸⁴⁹

HVKITDFGLA

⁸⁵⁹

KLLGAEEKVP

⁸⁷⁷

IKWMALESIL

⁸⁸⁷

HRIYTHQSDV

⁸⁹⁷

WSYGVTVWEL

⁹⁰⁷

MTFGSKPYDG

⁹¹⁷

IPASEISSIL

⁹²⁷

EKGERLPQPP

⁹³⁷

ICTIDVYMIM

⁹⁴⁷

VKCWMIDADS

⁹⁵⁷

RPKFRELIIE

⁹⁶⁷

FSKMARDPQR

⁹⁷⁷

YLVIQGDERM

⁹⁸⁷

SNFYRALMDE

¹⁰⁰⁴

VVDADEYLI

Residue

Distance (Å)

LEU718

3.870

GLY719

4.124

VAL726

3.854

ALA743

3.334

ILE744

4.349

LYS745

3.414

MET766

3.317

CYS775

3.424

ARG776

3.123

LEU777

3.371

LEU788

3.100

ILE789

4.160

THR790

3.138

GLN791

3.195

Residue

Distance (Å)

LEU792

3.715

MET793

2.960

GLY796

3.809

CYS797

3.130

LEU799

3.534

ASP800

3.057

ARG803

3.623

ARG841

4.149

LEU844

3.375

THR854

3.596

ASP855

3.483

PHE856

3.479

LEU858

3.841

MET1002

4.023

Ligand Name: Brigatinib

Ligand Info

Structure Description

Studies Towards a Reversible EGFR C797S Triple Mutant Inhibitor Series

PDB:7AEM

Method

X-ray diffraction

Resolution

2.65 Å

Mutation

[197]

PDB Sequence

SGEAPNQALL

⁷⁰⁴

RILKETEFKK

⁷¹⁴

IKVLGSGAFG

⁷²⁴

TVYKGLWIPE

⁷³⁴

GEKVKIPVAI

⁷⁴⁴

KELATSPKAN

⁷⁵⁶

KEILDEAYVM

⁷⁶⁶

ASVDNPHVCR

⁷⁷⁶

LLGICLTSTV

⁷⁸⁶

QLITQLMPFG

⁷⁹⁶

CLLDYVREHK

⁸⁰⁶

DNIGSQYLLN

⁸¹⁶

WCVQIAKGMN

⁸²⁶

YLEDRRLVHR

⁸³⁶

DLAARNVLVK

⁸⁴⁶

TPQHVKITDF

⁸⁵⁶

GLAKLLGAEE

⁸⁶⁶

KEYHAEGGKV

⁸⁷⁶

PIKWMALESI

⁸⁸⁶

LHRIYTHQSD

⁸⁹⁶

VWSYGVTVWE

⁹⁰⁶

LMTFGSKPYD

⁹¹⁶

GIPASEISSI

⁹²⁶

LEKGERLPQP

⁹³⁶

PICTIDVYMI

⁹⁴⁶

MVKCWMIDAD

⁹⁵⁶

SRPKFRELII

⁹⁶⁶

EFSKMARDPQ

⁹⁷⁶

RYLVIQGDER

⁹⁸⁶

MHLPLMDEED

¹⁰⁰⁶

MDDVVDADEY

¹⁰¹⁶

Residue

Distance (Å)

LEU718

3.663

GLY719

3.649

PHE723

3.562

VAL726

3.766

ALA743

3.266

LYS745

4.226

THR790

3.893

GLN791

3.498

LEU792

3.620

MET793

2.921

PRO794

3.438

Residue

Distance (Å)

PHE795

4.917

GLY796

3.086

CYS797

4.105

ASP800

4.640

GLU804

3.632

ARG841

3.627

ASN842

4.415

LEU844

3.425

THR854

4.115

ASP855

4.115

Click to View More Binding Site Information of This Target with Different Ligands

Different Human System Profiles of Target	Top
Human Similarity Proteins of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target. A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs (Brief Bioinform, 21: 649-662, 2020). Human Tissue Distribution of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues. The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects (Nat Rev Drug Discov, 20: 64-81, 2021). Human Pathway Affiliation of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function. Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes (Pharmacol Rev, 58: 259-279, 2006). Biological Network Descriptors of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database. The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information (Front Pharmacol, 9, 1245, 2018; Curr Opin Struct Biol. 44:134-142, 2017). Human Similarity Proteins Human Tissue Distribution Human Pathway Affiliation Biological Network Descriptors

Different Human System Profiles of Target

Top

Human Similarity Proteins of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.

A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs (Brief Bioinform, 21: 649-662, 2020).

Human Tissue Distribution of target is determined from a proteomics study that quantified more than 12,000 genes across 32 normal human tissues. Tissue Specificity (TS) score was used to define the enrichment of target across tissues.

The distribution of targets among different tissues or organs need to be taken into consideration when assessing the target druggability, as it is generally accepted that the wider the target distribution, the greater the concern over potential adverse effects (Nat Rev Drug Discov, 20: 64-81, 2021).

Human Pathway Affiliation of target is determined by the life-essential pathways provided on KEGG database. The target-affiliated pathways were defined based on the following two criteria (a) the pathways of the studied target should be life-essential for both healthy individuals and patients, and (b) the studied target should occupy an upstream position in the pathways and therefore had the ability to regulate biological function.

Targets involved in a fewer pathways have greater likelihood to be successfully developed, while those associated with more human pathways increase the chance of undesirable interferences with other human processes (Pharmacol Rev, 58: 259-279, 2006).

Biological Network Descriptors of target is determined based on a human protein-protein interactions (PPI) network consisting of 9,309 proteins and 52,713 PPIs, which were with a high confidence score of ≥ 0.95 collected from STRING database.

The network properties of targets based on protein-protein interactions (PPIs) have been widely adopted for the assessment of target’s druggability. Proteins with high node degree tend to have a high impact on network function through multiple interactions, while proteins with high betweenness centrality are regarded to be central for communication in interaction networks and regulate the flow of signaling information (Front Pharmacol, 9, 1245, 2018; Curr Opin Struct Biol. 44:134-142, 2017).

Human Similarity Proteins

Human Tissue Distribution

Human Pathway Affiliation

Biological Network Descriptors

Protein Name	Pfam ID	Percentage of Identity (%)	E value
Mixed lineage kinase 1 (MAP3K9)	PF00069 ; PF14604	32.432 (96/296)	4.02E-32
Serine/threonine-protein kinase 25 (STK25)	PF00069	32.843 (67/204)	1.05E-20
Serine/threonine-protein kinase PAK 3 (PAK3)	PF00786 ; PF00069	29.630 (80/270)	1.09E-18
MST-1 protein kinase (STK4)	PF11629 ; PF00069	29.858 (63/211)	5.30E-18
Ribosomal protein S6 kinase alpha-1 (RSK1)	PF00069 ; PF00433	28.879 (67/232)	9.35E-18
PAK-1 protein kinase (PAK1)	PF00786 ; PF00069	27.778 (75/270)	1.38E-17
Serine/threonine-protein kinase 24 (STK24)	PF00069	30.500 (61/200)	2.86E-17
Serine/threonine-protein kinase 26 (STK26)	PF00069	31.343 (63/201)	4.26E-17
Serine/threonine-protein kinase 3 (STK3)	PF11629 ; PF00069	28.910 (61/211)	8.72E-17
Ste-20-related kinase (STK39)	PF12202 ; PF00069	28.509 (65/228)	1.02E-16
PKC-delta-interacting protein kinase (RIPK4)	PF12796 ; PF00069	29.286 (82/280)	1.49E-16
Ribosomal protein S6 kinase alpha-3 (RSK3)	PF00069 ; PF00433	27.826 (64/230)	1.54E-16
Ribosomal protein S6 kinase alpha-2 (RSK2)	PF00069 ; PF00433	28.139 (65/231)	1.87E-16
ERK activator kinase 5 (MAP2K5)	PF00564 ; PF00069	28.505 (61/214)	2.01E-16
NIMA-related kinase 6 (NEK6)	PF00069	25.641 (60/234)	3.21E-16
Unc-51 like kinase 3 (ULK3)	PF04212 ; PF00069	26.275 (67/255)	3.48E-16
PAK-2 protein kinase (PAK2)	PF00786 ; PF00069	27.407 (74/270)	4.85E-16
SPS1/STE20-related protein kinase YSK4 (YSK4)	PF00069	29.268 (60/205)	5.44E-16
NIMA-related kinase 7 (NEK7)	PF00069	24.464 (57/233)	7.09E-16
MAPK/ERK kinase kinase 1 (MAP3K1)	PF00069	23.985 (65/271)	1.03E-15
Microtubule affinity regulating kinase 3 (MARK3)	PF02149 ; PF00069 ; PF00627 More >>	26.840 (62/231)	1.04E-15
Ribosomal protein S6 kinase alpha-6 (RSK6)	PF00069 ; PF00433	28.085 (66/235)	1.07E-15
Serine/threonine-protein kinase ULK1 (ULK1)	PF12063 ; PF00069	24.898 (61/245)	2.21E-15
Hormonally up-regulated neu tumor-associated kinase (HUNK)	PF00069	29.048 (61/210)	2.23E-15
Serine/threonine-protein kinase Nek11 (NEK11)	PF00069	28.643 (57/199)	2.56E-15
Oxidative stress responsive 1 (OXSR1)	PF12202 ; PF00069	27.193 (62/228)	3.42E-15
WNK lysine-deficient protein kinase 3 (WNK3)	PF12202 ; PF00069	30.846 (62/201)	4.16E-15
Apoptosis signal-regulating kinase 2 (MAP3K6)	PF19039 ; PF20309 ; PF20302 ; PF13281 ; PF00069 More >>	26.333 (79/300)	8.89E-15
Serine/threonine-protein kinase ULK2 (ULK2)	PF12063 ; PF00069	23.750 (57/240)	1.10E-14
ERK activator kinase 1 (MEK1)	PF00069	27.386 (66/241)	1.66E-14
Aurora kinase A (AURKA)	PF00069	23.574 (62/263)	1.83E-14
Apoptosis signal-regulating kinase 1 (MAP3K5)	PF19039 ; PF20309 ; PF20302 ; PF13281 ; PF00069 More >>	27.473 (75/273)	1.96E-14
ERK activator kinase 7 (MAP2K7)	PF00069	25.856 (68/263)	2.51E-14
Serine/threonine-protein kinase WNK1 (WNK1)	PF12202 ; PF00069	30.622 (64/209)	2.66E-14
Salt-inducible kinase 2 (SIK2)	PF00069	29.435 (73/248)	3.32E-14
MAP/microtubule affinity-regulating kinase 4 (MARK4)	PF02149 ; PF00069 ; PF00627 More >>	25.877 (59/228)	3.59E-14
Serine/threonine-protein kinase 10 (STK10)	PF00069 ; PF12474	28.426 (56/197)	3.70E-14
Protein kinase C alpha (PRKCA)	PF00130 ; PF00168 ; PF00069 ; PF00433 More >>	26.172 (67/256)	4.16E-14
Serine/threonine-protein kinase 33 (STK33)	PF00069	29.870 (69/231)	4.28E-14
Dual specificity mitogen-activated protein kinase kinase 4 (MAP2K4)	PF00069	28.837 (62/215)	4.46E-14
MAPK/ERK kinase kinase 3 (MAP3K3)	PF00564 ; PF00069	27.206 (74/272)	4.98E-14
Dual specificity mitogen-activated protein kinase kinase 6 (MAP2K6)	PF00069	27.206 (74/272)	5.20E-14
Serine/threonine-protein kinase WNK2 (WNK2)	PF12202 ; PF00069	30.288 (63/208)	5.99E-14
Cyclin-dependent kinase 6 (CDK6)	PF00069	26.457 (59/223)	7.82E-14
ERK activator kinase 2 (MEK2)	PF00069	26.877 (68/253)	7.95E-14
Serine/threonine-protein kinase Nek5 (NEK5)	PF00069	22.745 (58/255)	9.01E-14
Receptor-interacting serine/threonine-protein kinase 3 (RIPK3)	PF00069 ; PF12721	27.241 (79/290)	9.07E-14
Phosphoinositide dependent protein kinase-1 (PDPK1)	PF14593 ; PF00069	27.962 (59/211)	9.93E-14
SNF-related serine/threonine-protein kinase (SNRK)	PF00069	27.907 (60/215)	1.23E-13
Serine/threonine-protein kinase Nek8 (NEK8)	PF00069 ; PF00415	26.923 (56/208)	1.27E-13
MAPK/ERK kinase kinase 2 (MAP3K2)	PF00564 ; PF00069	27.338 (76/278)	1.64E-13
Testis-specific serine/threonine-protein kinase 4 (TSSK4)	PF00069	27.950 (45/161)	2.76E-13
Cyclin-dependent kinase 3 (CDK3)	PF00069	26.667 (56/210)	3.36E-13
Myosin-IIIa (MYO3A)	PF00612 ; PF00063 ; PF00069 More >>	26.966 (72/267)	3.77E-13
Cyclin-dependent kinase 2 (CDK2)	PF00069	26.214 (54/206)	3.79E-13
Serine/threonine-protein kinase MARK2 (MARK2)	PF02149 ; PF00069 ; PF00627 More >>	26.106 (59/226)	5.02E-13
Putative 3-phosphoinositide-dependent protein kinase 2 (PDPK2P)	PF00069	27.488 (58/211)	5.12E-13
Protein kinase C theta (PRKCQ)	PF00130 ; PF00069 ; PF00433 More >>	24.055 (70/291)	5.29E-13
STE20-related serine/threonine-protein kinase (SLK)	PF00069 ; PF12474	26.482 (67/253)	5.96E-13
Serine/threonine-protein kinase 32A (STK32A)	PF00069	25.359 (53/209)	6.39E-13
NUAK family SNF1-like kinase 2 (NUAK2)	PF00069	26.295 (66/251)	6.69E-13
Mitogen-activated protein kinase kinase kinase 15 (MAP3K15)	PF19039 ; PF20309 ; PF20302 ; PF13281 ; PF00069 More >>	29.703 (60/202)	7.97E-13
Serine/threonine-protein kinase D2 (PRKD2)	PF00130 ; PF00069	29.327 (61/208)	8.17E-13
Serine/threonine-protein kinase MARK1 (MARK1)	PF02149 ; PF00069 ; PF00627 More >>	25.664 (58/226)	9.32E-13
Ribosomal protein S6 kinase beta-2 (RPS6KB2)	PF00069 ; PF00433	25.207 (61/242)	1.09E-12
Fused homolog (STK36)	PF13646 ; PF00069	23.744 (52/219)	1.60E-12
Polo-like kinase 4 (PLK4)	PF00069 ; PF18190 ; PF18409 More >>	27.273 (57/209)	2.17E-12
Cyclin-dependent kinase 1 (CDK1)	PF00069	26.442 (55/208)	2.25E-12
Leucine-rich repeat serine/threonine-protein kinase 1 (LRRK1)	PF12796 ; PF16095 ; PF00069 ; PF08477 More >>	25.260 (73/289)	2.36E-12
Serine/threonine-protein kinase WNK4 (WNK4)	PF12202 ; PF00069	27.805 (57/205)	2.65E-12
Serine/threonine-protein kinase Nek3 (NEK3)	PF00069	24.757 (51/206)	2.95E-12
Leucine-rich repeat kinase 2 (LRRK2)	PF16095 ; PF12799 ; PF13855 ; PF00069 ; PF08477 More >>	27.311 (65/238)	3.29E-12
Cyclin-dependent kinase 7 (CDK7)	PF00069	25.000 (52/208)	3.39E-12
Protein kinase D (PRKD1)	PF00130 ; PF00169 ; PF00069 More >>	28.365 (59/208)	3.42E-12
cAMP-dependent protein kinase catalytic subunit PRKX (PRKX)	PF00069	23.451 (53/226)	5.05E-12
Serine/threonine-protein kinase Nek4 (NEK4)	PF00069	24.046 (63/262)	7.37E-12
cAMP-dependent protein kinase catalytic subunit gamma (PRKACG)	PF00069	22.530 (57/253)	8.74E-12
Cyclin-dependent kinase 5 (CDK5)	PF00069	23.707 (55/232)	9.04E-12
Putative serine/threonine-protein kinase PRKY (PRKY)	PF00069	23.744 (52/219)	9.18E-12
Maternal embryonic leucine zipper kinase (MELK)	PF02149 ; PF00069	25.296 (64/253)	9.60E-12
SIK family kinase 3 (SIK3)	PF00069	25.442 (72/283)	9.78E-12
Tyrosine-protein kinase EIF2AK2 (p68)	PF00035 ; PF00069	24.621 (65/264)	1.16E-11
Serine/threonine-protein kinase Nek9 (NEK9)	PF00069 ; PF00415	23.864 (63/264)	1.26E-11
Ribosomal protein S6 kinase beta-1 (S6K1)	PF00069 ; PF00433	25.397 (64/252)	1.28E-11
Protein kinase C delta (PRKCD)	PF00130 ; PF00069 ; PF00433 More >>	28.302 (60/212)	1.49E-11
Serine/threonine-protein kinase Nek10 (NEK10)	PF00069	25.926 (70/270)	1.54E-11
5'-AMP-activated protein kinase catalytic subunit alpha-1 (PRKAA1)	PF16579 ; PF00069	29.064 (59/203)	1.56E-11
Omphalocele kinase 1 (NUAK1)	PF00069	23.843 (67/281)	1.62E-11
Protein kinase C beta (PRKCB)	PF00130 ; PF00168 ; PF00069 ; PF00433 More >>	24.473 (58/237)	1.64E-11
Cyclin-dependent kinase 20 (CDK20)	PF00069	25.616 (52/203)	1.74E-11
Myosin light chain kinase 3 (MYLK3)	PF00069	25.097 (65/259)	1.93E-11
Protein kinase G1 (PRKG1)	PF00027 ; PF16808 ; PF00069 More >>	23.810 (55/231)	2.01E-11
cAMP-dependent protein kinase catalytic subunit alpha (PRKACA)	PF00069	23.810 (55/231)	2.09E-11
Serine/threonine-protein kinase D3 (PRKD3)	PF00130 ; PF00169 ; PF00069 More >>	27.536 (57/207)	2.14E-11
Yet another novel kinase 2 (STK32B)	PF00069	22.530 (57/253)	2.17E-11
Cyclin-dependent kinase 15 (CDK15)	PF00069	23.894 (54/226)	2.59E-11
Aurora kinase C (AURKC)	PF00069	25.000 (61/244)	3.31E-11
Cyclin-dependent kinase 4 (CDK4)	PF00069	25.778 (58/225)	3.89E-11
TRAF2 and NCK interacting kinase (TNIK)	PF00780 ; PF00069	24.885 (54/217)	4.67E-11
Serine/threonine-protein kinase pim-2 (PIM2)	PF00069	25.279 (68/269)	4.68E-11
Cyclin-dependent kinase 14 (CDK14)	PF00069	25.490 (52/204)	8.38E-11
5'-AMP-activated protein kinase catalytic subunit alpha-2 (PRKAA2)	PF16579 ; PF00069	24.415 (73/299)	8.46E-11
Cyclin-dependent kinase 17 (CDK17)	PF12330 ; PF00069	25.490 (52/204)	8.52E-11
Cyclin-dependent kinase-like 2 (CDKL2)	PF00069	23.077 (81/351)	1.01E-10
cAMP-dependent protein kinase catalytic subunit beta (PRKACB)	PF00069	24.286 (51/210)	1.27E-10
Myosin light chain kinase family member 4 (MYLK4)	PF00069	25.197 (64/254)	1.39E-10
Misshapen-like kinase 1 (MINK1)	PF00780 ; PF00069	25.926 (56/216)	1.49E-10
Putative serine/threonine-protein kinase SIK1B (SIK1B)	PF00069	26.432 (60/227)	1.58E-10
Salt-inducible kinase 1 (SIK1)	PF00069	26.432 (60/227)	1.66E-10
Protein kinase G2 (PRKG2)	PF00027 ; PF00069	23.443 (64/273)	1.66E-10
Ribosomal protein S6 kinase alpha-5 (RSK5)	PF00069 ; PF00433	29.004 (67/231)	1.66E-10
Testis-specific serine/threonine-protein kinase 6 (TSSK6)	PF00069	26.293 (61/232)	2.41E-10
Cyclin-dependent kinase-like 3 (CDKL3)	PF00069	26.047 (56/215)	2.46E-10
Extracellular signal-regulated kinase 1 (ERK1)	PF00069	23.153 (47/203)	2.52E-10
NIMA-related kinase 1 (NEK1)	PF00069	23.415 (48/205)	3.83E-10
Proto-oncogene serine/threonine-protein kinase mos (MOS)	PF00069	22.867 (67/293)	3.86E-10
Death-associated protein kinase 3 (DAPK3)	PF00069	28.169 (60/213)	3.94E-10
Serine/threonine-protein kinase TAO2 (TAOK2)	PF00069	26.961 (55/204)	4.37E-10
Death-associated protein kinase 2 (DAPK2)	PF00069	27.155 (63/232)	4.72E-10
Protein kinase C iota (PRKCI)	PF00130 ; PF00564 ; PF00069 ; PF00433 More >>	23.207 (55/237)	4.91E-10
TAO kinase 1 (TAOK1)	PF00069	26.866 (54/201)	5.33E-10
BR serine/threonine kinase 1 (BRSK1)	PF00069	25.893 (58/224)	5.93E-10
Serine/threonine-protein kinase Sgk3 (SGK3)	PF00069 ; PF00433 ; PF00787 More >>	26.190 (55/210)	6.03E-10
Myosin-IIIb (MYO3B)	PF00612 ; PF00063 ; PF00069 More >>	25.000 (69/276)	6.26E-10
Serine/threonine-protein kinase Chk2 (RAD53)	PF00498 ; PF00069	24.172 (73/302)	7.81E-10
Microtubule-associated serine/threonine-protein kinase 3 (MAST3)	PF08926 ; PF17820 ; PF02163 ; PF00069 More >>	23.643 (61/258)	7.88E-10
Cyclin-dependent kinase 16 (CDK16)	PF12330 ; PF00069	26.087 (54/207)	9.53E-10
Mitogen-activated protein kinase 15 (MAPK15)	PF00069	27.143 (57/210)	1.00E-09
Serine/threonine-protein kinase Sgk1 (SGK1)	PF00069 ; PF00433	24.675 (57/231)	1.07E-09
Serine/threonine-protein kinase ICK (CILK1)	PF00069	26.577 (59/222)	1.26E-09
BR serine/threonine kinase 2 (BRSK2)	PF00069	26.364 (58/220)	1.30E-09
Myosin light kinase (MYLK)	PF16620 ; PF00041 ; PF07679 ; PF00069 More >>	25.243 (52/206)	1.37E-09
Protein kinase C gamma (PRKCG)	PF00130 ; PF00168 ; PF00069 ; PF00433 More >>	29.268 (36/123)	1.49E-09
Protein kinase C zeta (PRKCZ)	PF00130 ; PF00564 ; PF00069 ; PF00433 More >>	23.950 (57/238)	1.54E-09
Mitogen-activated protein kinase 13 (MAPK13)	PF00069	28.287 (71/251)	1.57E-09
MAP kinase p38 (MAPK12)	PF00069	30.097 (62/206)	1.62E-09
Dual specificity mitogen-activated protein kinase kinase 3 (MAP2K3)	PF00069	28.511 (67/235)	1.66E-09
Ribosomal protein S6 kinase alpha-4 (RPS6KA4)	PF00069 ; PF00433	27.907 (60/215)	1.88E-09
MEK kinase kinase 4 (MAP4K4)	PF00780 ; PF00069	25.000 (54/216)	1.94E-09
Protein kinase N1 (PKN1)	PF02185 ; PF00069 ; PF00433 More >>	26.667 (72/270)	1.96E-09
Microtubule-associated serine/threonine-protein kinase 4 (MAST4)	PF08926 ; PF17820 ; PF02163 ; PF00069 More >>	23.077 (63/273)	2.20E-09
Serine/threonine-protein kinase H2 (PSKH2)	PF00069	25.108 (58/231)	2.48E-09
Serine/threonine-protein kinase PAK 5 (PAK5)	PF00786 ; PF00069	23.429 (41/175)	2.64E-09
Nik-related protein kinase (NRK)	PF00780 ; PF00069	30.827 (41/133)	2.89E-09
Serine/threonine-protein kinase PLK3 (PLK3)	PF00069 ; PF00659	24.878 (51/205)	3.35E-09
Calcium/calmodulin-dependent protein kinase type 1G (CAMK1G)	PF00069	26.733 (54/202)	3.52E-09
Protein kinase C eta type (PRKCH)	PF00130 ; PF00168 ; PF00069 ; PF00433 More >>	22.981 (74/322)	3.71E-09
Cyclin-dependent kinase 18 (CDK18)	PF00069	24.390 (50/205)	4.09E-09
Death-associated protein kinase 1 (DAPK1)	PF00023 ; PF12796 ; PF13637 ; PF00531 ; PF00069 More >>	27.751 (58/209)	5.48E-09
Myosin light chain kinase 2 (MYLK2)	PF00069	26.829 (55/205)	5.55E-09
Serine/threonine-protein kinase PAK 6 (PAK6)	PF00786 ; PF00069	24.500 (49/200)	6.08E-09
Serine/threonine-protein kinase 32C (STK32C)	PF00069	21.333 (48/225)	7.43E-09
Cytoplasmic DRAK1 (STK17A)	PF00069	27.053 (56/207)	9.17E-09
Microtubule-associated serine/threonine-protein kinase 1 (MAST1)	PF08926 ; PF17820 ; PF00069 More >>	24.895 (59/237)	9.27E-09
Cyclin-dependent kinase 13 (CDK13)	PF12330 ; PF00069	24.766 (53/214)	1.17E-08
MAPK/ERK kinase kinase 4 (MAP3K4)	PF19431 ; PF00069	24.878 (51/205)	1.24E-08
Calcium/calmodulin-dependent protein kinase type 1 (CAMK1)	PF00069	26.786 (60/224)	1.26E-08
Extracellular signal-regulated kinase 2 (ERK2)	PF00069	21.675 (44/203)	1.36E-08
Microtubule-associated serine/threonine-protein kinase 2 (MAST2)	PF08926 ; PF17820 ; PF00069 More >>	24.242 (56/231)	1.53E-08
MEK kinase kinase 3 (MAP4K3)	PF00780 ; PF00069	25.446 (57/224)	1.65E-08
Cyclin-dependent kinase 12 (CDK12)	PF00069	24.889 (56/225)	1.84E-08
Inhibitor of nuclear factor kappa-B kinase beta (IKKB)	PF18397 ; PF12179 ; PF00069 More >>	25.439 (58/228)	1.92E-08
Stress-activated protein kinase 2a (p38 alpha)	PF00069	28.302 (60/212)	1.94E-08
Extracellular signal-regulated kinase 5 (ERK5)	PF00069	24.057 (51/212)	2.25E-08
PRKR-like endoplasmic reticulum kinase (PERK)	PF00069	31.731 (33/104)	2.31E-08
NIMA-related kinase 2 (NEK2)	PF00069	22.097 (59/267)	2.74E-08
Testis-specific serine kinase 2 (TSSK2)	PF00069	25.847 (61/236)	2.74E-08
Cyclin-dependent kinase 9 (CDK9)	PF00069	22.749 (48/211)	3.56E-08
Glycogen synthase kinase-3 beta (GSK-3B)	PF00069	25.664 (58/226)	4.72E-08
Serine/threonine-protein kinase greatwall (MASTL)	PF00069	27.389 (43/157)	6.06E-08
Glycogen synthase kinase-3 alpha (GSK-3A)	PF00069	25.446 (57/224)	6.85E-08
PDZ binding kinase (PBK)	PF00069	25.150 (42/167)	6.89E-08
TAO kinase 3 (TAOK3)	PF00069	27.692 (54/195)	8.14E-08
MEK kinase kinase 1 (MAP4K1)	PF00780 ; PF00069	23.913 (55/230)	8.27E-08
Calcium/calmodulin-dependent protein kinase type IV (CAMK4)	PF00069	28.218 (57/202)	8.94E-08
PAK-4 protein kinase (PAK4)	PF00786 ; PF00069	23.429 (41/175)	9.16E-08
Serine/threonine-protein kinase MAK (MAK)	PF00069	24.623 (49/199)	9.37E-08
Serine/threonine-protein kinase NLK (NLK)	PF00069	25.248 (51/202)	1.01E-07
NDR1 protein kinase (STK38)	PF00069 ; PF00433	22.330 (69/309)	1.05E-07
Stress-activated protein kinase JNK3 (JNK3)	PF00069	27.885 (58/208)	1.26E-07
Serine/threonine-protein kinase Sgk2 (SGK2)	PF00069 ; PF00433	22.807 (52/228)	1.40E-07
Stress-activated protein kinase 2b (p38 beta)	PF00069	26.087 (54/207)	1.44E-07
PAS domain-containing serine/threonine-protein kinase (PASK)	PF13426 ; PF00069	25.234 (54/214)	1.51E-07
Calmodulin-dependent kinase II (CAMKK2)	PF00069	23.353 (39/167)	1.58E-07
RAC-gamma serine/threonine-protein kinase (AKT3)	PF00169 ; PF00069 ; PF00433 More >>	24.121 (48/199)	1.82E-07
Polo-like kinase 1 (PLK1)	PF00069 ; PF00659	28.947 (44/152)	2.09E-07
Citron Rho-interacting kinase (CIT)	PF00780 ; PF00169 ; PF00069 More >>	23.810 (45/189)	2.15E-07
Doublecortin-like kinase 2 (DCLK2)	PF03607 ; PF00069	26.214 (54/206)	2.19E-07
Cyclin-dependent kinase-like 1 (CDKL1)	PF00069	23.267 (47/202)	2.63E-07
Stress-activated protein kinase JNK1 (JNK1)	PF00069	27.404 (57/208)	3.00E-07
Ribosomal protein S6 kinase-related protein (RSKR)	PF00069	34.940 (29/83)	3.31E-07
G protein-coupled receptor kinase 6 (GRK6)	PF00069 ; PF00615	24.638 (51/207)	3.40E-07
G protein-coupled receptor kinase 4 (GRK4)	PF00069 ; PF00615	26.066 (55/211)	3.50E-07
Obscurin (OBSCN)	PF00041 ; PF07679 ; PF00612 ; PF00069 ; PF00621 More >>	26.601 (54/203)	3.89E-07
Stress-activated protein kinase JNK2 (JNK2)	PF00069	27.805 (57/205)	4.18E-07
Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform (PHKG1)	PF00069	27.778 (60/216)	4.21E-07
RAC-beta serine/threonine-protein kinase (AKT2)	PF00169 ; PF00069 ; PF00433 More >>	23.645 (48/203)	4.21E-07
Serine/threonine-protein kinase pim-1 (PIM1)	PF00069	23.982 (53/221)	4.76E-07
Cyclin-dependent kinase-like 4 (CDKL4)	PF00069	22.059 (45/204)	5.33E-07
Serine/threonine-protein kinase H1 (PSKH1)	PF00069	24.878 (51/205)	6.12E-07
Mitogen-activated protein kinase kinase kinase kinase 5 (MAP4K5)	PF00780 ; PF00069	23.636 (52/220)	6.13E-07
Cyclin-dependent kinase 11A (CDK11A)	PF00069	25.000 (51/204)	6.17E-07
Homeodomain-interacting protein kinase 4 (HIPK4)	PF00069	27.193 (62/228)	6.48E-07
TBC domain-containing protein kinase-like protein (TBCK)	PF00069 ; PF00566 ; PF00581 More >>	24.324 (45/185)	7.77E-07
Calcium/calmodulin-dependent protein kinase type II subunit delta (CAMK2D)	PF08332 ; PF00069	25.000 (53/212)	8.11E-07
Testis-specific serine/threonine-protein kinase 1 (TSSK1B)	PF00069	25.000 (53/212)	9.54E-07
Serine/threonine-protein kinase tousled-like 2 (TLK2)	PF00069	24.221 (70/289)	1.07E-06
G protein-coupled receptor kinase 5 (GRK5)	PF00069 ; PF00615	26.512 (57/215)	1.10E-06
Inhibitor of nuclear factor kappa-B kinase subunit epsilon (IKBKE)	PF00069 ; PF18394 ; PF18396 More >>	24.766 (53/214)	1.15E-06
Rhodopsin kinase GRK1 (GRK1)	PF00069 ; PF00615	34.375 (33/96)	1.16E-06
Endoplasmic reticulum to nucleus signaling 1 (ERN1)	PF00069 ; PF06479	28.251 (63/223)	1.17E-06
Protein kinase N3 (PKN3)	PF02185 ; PF00069 ; PF00433 More >>	25.306 (62/245)	1.27E-06
Cyclin-dependent kinase 10 (CDK10)	PF00069	25.463 (55/216)	1.28E-06
Bone morphogenetic protein receptor (BMPR2)	PF01064 ; PF00069	24.294 (86/354)	1.29E-06
Serine/threonine kinase-like domain-containing protein STKLD1 (STKLD1)	PF00069	23.529 (28/119)	1.31E-06
NF-kappa-B-activating kinase (TBK1)	PF00069 ; PF18394 ; PF18396 More >>	26.168 (56/214)	1.35E-06
Serine/threonine-protein kinase NIM1 (NIM1K)	PF00069	25.909 (57/220)	1.37E-06
Phosphorylase kinase testis gamma 2 (PHKG2)	PF00069	23.504 (55/234)	1.37E-06
Serine/threonine-protein kinase/endoribonuclease IRE2 (ERN2)	PF00069 ; PF06479	25.896 (65/251)	1.39E-06
Cyclin-dependent kinase-like 5 (CDKL5)	PF00069	24.000 (48/200)	1.70E-06
Mitogen-activated protein kinase 4 (MAPK4)	PF00069	23.005 (49/213)	1.79E-06
Cyclin-dependent kinase 11B (CDK11B)	PF00069	25.616 (52/203)	1.86E-06
Protein kinase N2 (PKN2)	PF02185 ; PF00069 ; PF00433 More >>	26.667 (64/240)	1.93E-06
PIM-3 protein kinase (PIM3)	PF00069	27.556 (62/225)	1.94E-06
TGF-beta-stimulated factor 1 (STK16)	PF00069	20.962 (61/291)	2.56E-06
RAC-alpha serine/threonine-protein kinase (AKT1)	PF00169 ; PF00069 ; PF00433 More >>	23.894 (54/226)	2.82E-06
Serine/threonine-protein kinase STK11 (STK11)	PF00069	22.674 (39/172)	2.91E-06
MEK kinase kinase 2 (MAP4K2)	PF00780 ; PF00069	23.618 (47/199)	3.07E-06
Serine/threonine-protein kinase 17B (STK17B)	PF00069	25.481 (53/208)	3.21E-06
NDR2 protein kinase (STK38L)	PF00069 ; PF00433	22.222 (74/333)	4.23E-06
Serine/threonine-protein kinase tousled-like 1 (TLK1)	PF00069	23.488 (66/281)	4.71E-06
Peripheral plasma membrane protein CASK (CASK)	PF00625 ; PF02828 ; PF00595 ; PF00069 ; PF00018 More >>	23.729 (56/236)	5.21E-06
MAPK/MAK/MRK overlapping kinase (MOK)	PF00069	21.256 (44/207)	5.37E-06
Cyclin-dependent kinase 19 (CDK19)	PF00069	27.273 (57/209)	5.98E-06
Calcium/calmodulin-dependent protein kinase type 1B (PNCK)	PF00069	23.875 (69/289)	7.26E-06
Aurora kinase B (AURKB)	PF00069	24.215 (54/223)	7.41E-06
Doublecortin-like kinase 3 (DCLK3)	PF00069	22.881 (54/236)	7.69E-06
Calcium/calmodulin-dependent protein kinase type 1D (CAMK1D)	PF00069	27.053 (56/207)	7.88E-06
TGF-beta receptor type I (TGFBR1)	PF01064 ; PF00069 ; PF08515 More >>	23.293 (58/249)	9.94E-06
Serine/threonine-protein kinase NIK (MAP3K14)	PF00069	27.513 (52/189)	1.10E-05
Rhodopsin kinase GRK7 (GRK7)	PF00069 ; PF00615	25.688 (56/218)	1.14E-05
Eukaryotic translation initiation factor 2-alpha kinase 4 (EIF2AK4)	PF12745 ; PF00069 ; PF05773 ; PF13393 More >>	26.797 (41/153)	1.26E-05
Inhibitor of nuclear factor kappa-B kinase alpha (IKKA)	PF18397 ; PF12179 ; PF00069 More >>	23.445 (49/209)	1.34E-05
Calcium/calmodulin-dependent protein kinase type II subunit gamma (CAMK2G)	PF08332 ; PF00069	23.113 (49/212)	1.41E-05
Anti-mullerian hormone II receptor (AMHR2)	PF00069	25.000 (41/164)	1.52E-05
Large tumor suppressor homolog 2 (LATS2)	PF00069 ; PF00433	20.561 (66/321)	1.55E-05
CaM-kinase IV kinase (CAMKK1)	PF00069	22.754 (38/167)	1.62E-05
Checkpoint kinase-1 (CHK1)	PF00069	25.359 (53/209)	1.89E-05
Serine/threonine-protein kinase SBK1 (SBK1)	PF00069	23.413 (59/252)	1.99E-05
Beta-adrenergic receptor kinase 1 (ADRBK1)	PF00169 ; PF00069 ; PF00615 More >>	24.651 (53/215)	2.33E-05
Doublecortin-like kinase 1 (DCLK1)	PF03607 ; PF00069	23.832 (51/214)	2.43E-05
Beta-adrenergic receptor kinase 2 (ADRBK2)	PF00169 ; PF00069 ; PF00615 More >>	24.651 (53/215)	2.45E-05
Activin receptor type IIA (ACVR2A)	PF01064 ; PF00069	21.918 (64/292)	2.70E-05
Eukaryotic translation initiation factor 2-alpha kinase 1 (EIF2AK1)	PF00069	31.132 (33/106)	3.05E-05
Casein kinase I alpha (CSNK1A1)	PF00069	26.144 (40/153)	3.07E-05
Protein kinase C epsilon (PRKCE)	PF00130 ; PF00168 ; PF00069 ; PF00433 More >>	22.222 (50/225)	3.55E-05
Polo-like kinase 2 (PLK2)	PF00069 ; PF00659	22.819 (34/149)	4.11E-05
Wee1-like protein kinase 2 (WEE2)	PF00069	26.056 (37/142)	4.47E-05
Rho-associated protein kinase 2 (ROCK2)	PF00069 ; PF08912	22.222 (48/216)	5.11E-05
STE20-related kinase adapter protein alpha (STRADA)	PF00069	21.304 (49/230)	5.57E-05
CDC42 binding protein kinase alpha (DMPK-like alpha)	PF00130 ; PF00780 ; PF08826 ; PF15796 ; PF00069 ; PF00433 More >>	23.810 (65/273)	6.72E-05
Cyclin-dependent kinase 8 (CDK8)	PF00069	34.375 (33/96)	7.77E-05
Activin receptor type IB (ACVR1B)	PF01064 ; PF00069 ; PF08515 More >>	23.695 (59/249)	8.96E-05
Extracellular matrix organizing protein FRAS1 (FRAS1)	PF16184 ; PF03160 ; PF00093 More >>	26.708 (43/161)	8.99E-05
Serine/threonine-protein kinase cot (COT)	PF00069	24.623 (49/199)	9.03E-05
Striated muscle preferentially expressed protein kinase (SPEG)	PF07679 ; PF00069 ; PF16650 More >>	25.833 (31/120)	9.20E-05
Rho-associated protein kinase 1 (ROCK1)	PF00069 ; PF08912	20.833 (45/216)	9.27E-05
Serine/threonine-protein kinase LATS1 (LATS1)	PF00069 ; PF00627	25.641 (40/156)	1.19E-04
Calcium/calmodulin-dependent protein kinase type II subunit alpha (CAMK2A)	PF08332 ; PF00069	24.528 (52/212)	1.30E-04
Wee1-like protein kinase (WEE1)	PF00069	23.592 (67/284)	1.43E-04
Casein kinase I isoform alpha-like (CSNK1A1L)	PF00069	26.144 (40/153)	1.54E-04
Testis-specific serine/threonine-protein kinase 3 (TSSK3)	PF00069	26.531 (39/147)	1.60E-04
Serine/threonine-protein kinase SBK2 (SBK2)	PF00069	27.419 (51/186)	1.66E-04
Activin receptor type IIB (ACVR2B)	PF01064 ; PF00069	22.477 (49/218)	2.57E-04
MAPK-activated protein kinase 3 (MAPKAPK3)	PF00069	25.751 (60/233)	3.76E-04
Kalirin (KALRN)	PF13716 ; PF00041 ; PF07679 ; PF00169 ; PF00069 ; PF00621 ; PF16609 ; PF00435 More >>	24.171 (51/211)	4.27E-04
Serine/threonine-protein kinase MRCK gamma (CDC42BPG)	PF00130 ; PF00780 ; PF08826 ; PF00069 More >>	24.771 (54/218)	4.78E-04
Casein kinase I gamma-2 (CSNK1G2)	PF12605 ; PF00069	23.684 (54/228)	5.53E-04
Tau-tubulin kinase 2 (TTBK2)	PF00069	22.034 (52/236)	5.63E-04
Casein kinase I gamma-3 (CSNK1G3)	PF12605 ; PF00069	22.807 (52/228)	5.69E-04
Serine/threonine-protein kinase 35 (STK35)	PF00069	21.583 (60/278)	6.06E-04
Serine/threonine-protein kinase ULK4 (ULK4)	PF00069	24.171 (51/211)	6.37E-04
Casein kinase I delta (CSNK1D)	PF00069	24.681 (58/235)	7.23E-04
CaM kinase-like vesicle-associated protein (CAMKV)	PF00069	24.309 (44/181)	7.81E-04
Dual-specificity tyrosine-phosphorylation regulated kinase 3 (DYRK3)	PF00069	21.569 (44/204)	8.95E-04
Casein kinase I epsilon (CSNK1E)	PF00069	23.750 (57/240)	1.00E-03
MAP kinase signal-integrating kinase 2 (MKNK2)	PF00069	27.211 (40/147)	1.00E-03
Calcium/calmodulin-dependent protein kinase type II subunit beta (CAMK2B)	PF08332 ; PF00069	23.005 (49/213)	1.00E-03
Homeodomain interacting protein kinase 2 (HIPK2)	PF00069	23.984 (59/246)	3.00E-03
IL-1 receptor-associated kinase 3 (IRAK3)	PF00531 ; PF00069	22.066 (47/213)	4.00E-03
Serine/threonine-protein kinase 40 (STK40)	PF00069	26.241 (37/141)	4.00E-03
Homeodomain-interacting protein kinase 1 (HIPK1)	PF00069	25.161 (39/155)	4.00E-03
Serine/threonine-protein kinase PDIK1L (PDIK1L)	PF00069	20.543 (53/258)	5.00E-03
Membrane-associated kinase (PKMYT1)	PF00069	22.381 (47/210)	5.00E-03
Homeodomain-interacting protein kinase 3 (HIPK3)	PF00069	20.352 (81/398)	5.00E-03
Tau-tubulin kinase (TTBK1)	PF00069	22.414 (52/232)	5.00E-03
Triple functional domain protein (TRIO)	PF00650 ; PF07679 ; PF00169 ; PF00069 ; PF00621 ; PF16609 ; PF00018 ; PF00435 More >>	25.000 (52/208)	5.00E-03
Click to Show/Hide the Information of Human Similarity Proteins


Note: If a protein has TS (tissue specficity) scores at least in one tissue >= 2.5, this protein is called tissue-enriched (including tissue-enriched-but-not-specific and tissue-specific). In the plots, the vertical lines are at thresholds 2.5 and 4.

KEGG Pathway	Pathway ID	Affiliated Target
MAPK signaling pathway	hsa04010	Affiliated Target
Class: Environmental Information Processing => Signal transduction	Pathway Hierarchy
ErbB signaling pathway	hsa04012	Affiliated Target
Class: Environmental Information Processing => Signal transduction	Pathway Hierarchy
Ras signaling pathway	hsa04014	Affiliated Target
Class: Environmental Information Processing => Signal transduction	Pathway Hierarchy
Rap1 signaling pathway	hsa04015	Affiliated Target
Class: Environmental Information Processing => Signal transduction	Pathway Hierarchy
Calcium signaling pathway	hsa04020	Affiliated Target
Class: Environmental Information Processing => Signal transduction	Pathway Hierarchy
HIF-1 signaling pathway	hsa04066	Affiliated Target
Class: Environmental Information Processing => Signal transduction	Pathway Hierarchy
FoxO signaling pathway	hsa04068	Affiliated Target
Class: Environmental Information Processing => Signal transduction	Pathway Hierarchy
Phospholipase D signaling pathway	hsa04072	Affiliated Target
Class: Environmental Information Processing => Signal transduction	Pathway Hierarchy
Endocytosis	hsa04144	Affiliated Target
Class: Cellular Processes => Transport and catabolism	Pathway Hierarchy
PI3K-Akt signaling pathway	hsa04151	Affiliated Target
Class: Environmental Information Processing => Signal transduction	Pathway Hierarchy
Focal adhesion	hsa04510	Affiliated Target
Class: Cellular Processes => Cellular community - eukaryotes	Pathway Hierarchy
Adherens junction	hsa04520	Affiliated Target
Class: Cellular Processes => Cellular community - eukaryotes	Pathway Hierarchy
Gap junction	hsa04540	Affiliated Target
Class: Cellular Processes => Cellular community - eukaryotes	Pathway Hierarchy
JAK-STAT signaling pathway	hsa04630	Affiliated Target
Class: Environmental Information Processing => Signal transduction	Pathway Hierarchy
Regulation of actin cytoskeleton	hsa04810	Affiliated Target
Class: Cellular Processes => Cell motility	Pathway Hierarchy
GnRH signaling pathway	hsa04912	Affiliated Target
Class: Organismal Systems => Endocrine system	Pathway Hierarchy
Estrogen signaling pathway	hsa04915	Affiliated Target
Class: Organismal Systems => Endocrine system	Pathway Hierarchy
Oxytocin signaling pathway	hsa04921	Affiliated Target
Class: Organismal Systems => Endocrine system	Pathway Hierarchy
Relaxin signaling pathway	hsa04926	Affiliated Target
Class: Organismal Systems => Endocrine system	Pathway Hierarchy
Parathyroid hormone synthesis, secretion and action	hsa04928	Affiliated Target
Class: Organismal Systems => Endocrine system	Pathway Hierarchy
Click to Show/Hide the Information of Affiliated Human Pathways

Degree	137	Degree centrality	1.47E-02	Betweenness centrality	2.54E-02
Closeness centrality	2.82E-01	Radiality	1.48E+01	Clustering coefficient	6.91E-02
Neighborhood connectivity	3.41E+01	Topological coefficient	2.04E-02	Eccentricity	11
Download	Click to Download the Full PPI Network of This Target

Chemical Structure based Activity Landscape of Target

Top

Drug Property Profile of Target

Top

(1) Molecular Weight (mw) based Drug Clustering

(2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering

(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering

(4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering

(5) Rotatable Bond Count (rotbonds) based Drug Clustering

(6) Topological Polar Surface Area (polararea) based Drug Clustering

"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five

Co-Targets

Top

Co-Targets

Co-Targets Info

Target Poor or Non Binders

Top

Target Poor or Non Binders

Target Poor or Non Binders Info

Target Regulators

Top

Target-regulating microRNAs

Target-regulating microRNAs Info

Target-regulating Transcription Factors

Target-regulating Transcription Factors Info

Target-interacting Proteins

Target-interacting Proteins Info

Target Profiles in Patients

Top

Target Expression
Profile (TEP)

Target Expression Profile Info

Drug Resistance
Mutation (DRM)

Drug Resistance Mutation Info

Target Affiliated Biological Pathways		Top
KEGG Pathway	[+] 32 KEGG Pathways	+
1	MAPK signaling pathway
2	ErbB signaling pathway
3	Ras signaling pathway
4	Rap1 signaling pathway
5	Calcium signaling pathway
6	Cytokine-cytokine receptor interaction
7	HIF-1 signaling pathway
8	FoxO signaling pathway
9	Endocytosis
10	PI3K-Akt signaling pathway
11	Dorso-ventral axis formation
12	Focal adhesion
13	Adherens junction
14	Gap junction
15	Regulation of actin cytoskeleton
16	GnRH signaling pathway
17	Estrogen signaling pathway
18	Oxytocin signaling pathway
19	Epithelial cell signaling in Helicobacter pylori infection
20	Hepatitis C
21	Pathways in cancer
22	Proteoglycans in cancer
23	MicroRNAs in cancer
24	Pancreatic cancer
25	Endometrial cancer
26	Glioma
27	Prostate cancer
28	Melanoma
29	Bladder cancer
30	Non-small cell lung cancer
31	Central carbon metabolism in cancer
32	Choline metabolism in cancer
NetPath Pathway	[+] 2 NetPath Pathways	+
1	IL4 Signaling Pathway
2	EGFR1 Signaling Pathway
Panther Pathway	[+] 2 Panther Pathways	+
1	Cadherin signaling pathway
2	EGF receptor signaling pathway
PID Pathway	[+] 19 PID Pathways	+
1	LPA receptor mediated events
2	Signaling events mediated by PTP1B
3	Arf6 signaling events
4	Signaling events mediated by TCPTP
5	Thromboxane A2 receptor signaling
6	SHP2 signaling
7	Regulation of Telomerase
8	EGF receptor (ErbB1) signaling pathway
9	EGFR-dependent Endothelin signaling events
10	Posttranslational regulation of adherens junction stability and dissassembly
11	Direct p53 effectors
12	ErbB1 downstream signaling
13	Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
14	E-cadherin signaling in keratinocytes
15	ErbB receptor signaling network
16	Internalization of ErbB1
17	Stabilization and expansion of the E-cadherin adherens junction
18	a6b1 and a6b4 Integrin signaling
19	Syndecan-3-mediated signaling events
Reactome	[+] 14 Reactome Pathways	+
1	Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
2	SHC1 events in ERBB2 signaling
3	PLCG1 events in ERBB2 signaling
4	PIP3 activates AKT signaling
5	GRB2 events in EGFR signaling
6	GAB1 signalosome
7	SHC1 events in EGFR signaling
8	EGFR downregulation
9	GRB2 events in ERBB2 signaling
10	PI3K events in ERBB2 signaling
11	EGFR Transactivation by Gastrin
12	Constitutive Signaling by Aberrant PI3K in Cancer
13	Constitutive Signaling by EGFRvIII
14	RAF/MAP kinase cascade
WikiPathways	[+] 29 WikiPathways	+
1	ErbB Signaling Pathway
2	Regulation of Actin Cytoskeleton
3	EGF/EGFR Signaling Pathway
4	MAPK Signaling Pathway
5	Focal Adhesion
6	Aryl Hydrocarbon Receptor Pathway
7	Extracellular vesicle-mediated signaling in recipient cells
8	TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer
9	Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
10	Bladder Cancer
11	Hair Follicle Development: Induction (Part 1 of 3)
12	Signaling by ERBB4
13	Signaling by ERBB2
14	Gastrin-CREB signalling pathway via PKC and MAPK
15	PIP3 activates AKT signaling
16	Nanoparticle-mediated activation of receptor signaling
17	Aryl Hydrocarbon Receptor
18	Spinal Cord Injury
19	Integrated Pancreatic Cancer Pathway
20	Gastric cancer network 2
21	AGE/RAGE pathway
22	Signaling Pathways in Glioblastoma
23	Arylhydrocarbon receptor (AhR) signaling pathway
24	miR-targeted genes in muscle cell - TarBase
25	miR-targeted genes in lymphocytes - TarBase
26	miR-targeted genes in epithelium - TarBase
27	Integrated Breast Cancer Pathway
28	Signaling by EGFR
29	L1CAM interactions

Target-Related Models and Studies

Top

Target Validation

Target Validation Info

Target QSAR Model

References

Top

REF 1

Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther. 2002 May;1(7):507-14.

REF 2

FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761210.

REF 3

FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059.

REF 4

URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5711).

REF 5

Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597-612.

REF 6

REF 7

BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs. 2008 Dec;9(12):1336-46.

REF 8

REF 9

2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.

REF 10

2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.

REF 11

Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

REF 12

REF 13

REF 14

Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.

REF 15

Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24.

REF 16

REF 17

FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 022059.

REF 18

REF 19

ClinicalTrials.gov (NCT00981058) First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin. U.S. National Institutes of Health.

REF 20

2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.

REF 21

The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.

REF 22

REF 23

2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.

REF 24

Nat Rev Drug Discov. 2013 Feb;12(2):87-90.

REF 25

REF 26

2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.

REF 27

REF 28

Clinical pipeline report, company report or official report of Beta Pharma.

REF 29

ClinicalTrials.gov (NCT02404675) High Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With EGFR 21 Exon Positive. U.S. National Institutes of Health.

REF 30

ClinicalTrials.gov (NCT03769506) ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy. U.S. National Institutes of Health.

REF 31

ClinicalTrials.gov (NCT04870190) Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases (ATTACK). U.S. National Institutes of Health.

REF 32

Clinical pipeline report, company report or official report of Klus Pharma

REF 33

ClinicalTrials.gov (NCT00130728) A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer

REF 34

ClinicalTrials.gov (NCT00598156) Chemotherapy and Avastin Followed by Maintenance Treatment With Avastin +/- Tarceva

REF 35

ClinicalTrials.gov (NCT02322281) TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy

REF 36

Clinical pipeline report, company report or official report of Daiichi Sankyo.

REF 37

Clinical pipeline report, company report or official report of Daiichi Sankyo.

REF 38

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 39

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021154)

REF 40

ClinicalTrials.gov (NCT01480479) Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma. U.S. National Institutes of Health.

REF 41

ClinicalTrials.gov (NCT00382031) Zalutumumab in Patients With Non-curable Head and Neck Cancer. U.S. National Institutes of Health.

REF 42

ClinicalTrials.gov (NCT00442533) Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors. U.S. National Institutes of Health.

REF 43

REF 44

ClinicalTrials.gov (NCT01614522) A Clinical Trial Evaluating the Effect of ASLAN001 in Patients With Recurrent/Metastatic Gastric Cancer Whose Tumors Are Either HER-2 Amplified or Co-expressing HER-1and HER-2. U.S. National Institutes of Health.

REF 45

REF 46

Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions. J Med Chem. 2000 Apr 6;43(7):1380-97.

REF 47

ClinicalTrials.gov (NCT02454842) Study for Treatment of Patients With EGFR Mutant, T790M-negative NSCLC (TH-4000). U.S. National Institutes of Health.

REF 48

REF 49

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035129)

REF 50

ClinicalTrials.gov (NCT02500927) A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naive Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations.

REF 51

A novel epidermal growth factor receptor inhibitor promotes apoptosis in non-small cell lung cancer cells resistant to erlotinib. Cancer Res. 2007 Jul 1;67(13):6253-62.

REF 52

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011 May 1;11(9):777-92.

REF 53

ClinicalTrials.gov (NCT02343406) Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas (INTELLANCE-2). U.S. National Institutes of Health.

REF 54

Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int J Cancer. 2006 Nov 1;119(9):2190-9.

REF 55

HER1-ECD vaccination dispenses with emulsification to elicit HER1-specific anti-proliferative effects. Hum Vaccin. 2009 Mar;5(3):158-65.

REF 56

REF 57

ClinicalTrials.gov (NCT02216916) Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy. U.S. National Institutes of Health.

REF 58

ClinicalTrials.gov (NCT00073541) A Study of the Safety and Effects of EMD 72000 in Subjects With Recurrent Ovarian Cancer. U.S. National Institutes of Health.

REF 59

ClinicalTrials.gov (NCT01577173) A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck

REF 60

ClinicalTrials.gov (NCT01652482) A Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wild-Type Metastatic Colorectal Cancer. U.S. National Institutes of Health.

REF 61

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer. Breast Cancer Res Treat. 2013 Jan;137(2):471-82.

REF 62

REF 63

ClinicalTrials.gov (NCT00067548) Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer. U.S. National Institutes of Health.

REF 64

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 65

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021633)

REF 66

REF 67

ClinicalTrials.gov (NCT00348790) Vatalanib in Treating Patients With Recurrent or Progressive Meningioma. U.S. National Institutes of Health.

REF 68

ClinicalTrials.gov (NCT04209465) A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. (MasterKey-01). U.S. National Institutes of Health.

REF 69

ClinicalTrials.gov (NCT03797391) A Dose Escalation Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors. U.S. National Institutes of Health.

REF 70

ClinicalTrials.gov (NCT03446417) A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer. U.S. National Institutes of Health.

REF 71

ClinicalTrials.gov (NCT04259450) Study to Assess AFM24 in Advanced Solid Cancers. U.S. National Institutes of Health.

REF 72

ClinicalTrials.gov (NCT04844073) A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (Also Known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer. U.S.National Institutes of Health.

REF 73

ClinicalTrials.gov (NCT01869166) Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)

REF 74

ClinicalTrials.gov (NCT03152435) EGFR CART Cells for Patients With Metastatic Colorectal Cancer

REF 75

Multiple infusions of anti-epidermal growth factor receptor (EGFR) monoclonal antibody (EMD 55,900) in patients with recurrent malignant gliomas. Eur J Cancer. 1996 Apr;32A(4):636-40.

REF 76

ClinicalTrials.gov (NCT01631279) A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors. U.S. National Institutes of Health.

REF 77

Clinical pipeline report, company report or official report of Shionogi (2011).

REF 78

A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73.

REF 79

ClinicalTrials.gov (NCT00676299) A Safety and Dose-finding Study of JNJ-26483327, a Drug in Development for Cancer, for Patients With Advanced and/or Refractory Solid Malignancies.. U.S. National Institutes of Health.

REF 80

ClinicalTrials.gov (NCT04036682) A Phase 1/2a Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer. U.S. National Institutes of Health.

REF 81

ClinicalTrials.gov (NCT04603287) A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors. U.S. National Institutes of Health.

REF 82

ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health.

REF 83

ClinicalTrials.gov (NCT02303678) D2C7 for Adult Patients With Recurrent Malignant Glioma. U.S. National Institutes of Health.

REF 84

ClinicalTrials.gov (NCT03526835) A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors. U.S. National Institutes of Health.

REF 85

ClinicalTrials.gov (NCT05387265) A Phase 1/1b, Open-label, Dose-finding, First-in-human Study to Evaluate the Safety and Antitumor Activity of CX-904, an EGFR-targeted T-cell Engager in Advanced Solid Tumors (CTMX-904-101). U.S.National Institutes of Health.

REF 86

ClinicalTrials.gov (NCT05647122) A Phase I, Multicenter, Open-label, First-in-Human, Dose Escalation and Expansion Study of AZD9592 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumors. U.S.National Institutes of Health.

REF 87

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020588)

REF 88

ClinicalTrials.gov (NCT02331693) CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR

REF 89

Clinical pipeline report, company report or official report of Genentech (2011).

REF 90

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032292)

REF 91

REF 92

ClinicalTrials.gov (NCT00003980) BIBX 1382 in Treating Patients With Solid Tumors. U.S. National Institutes of Health.

REF 93

ClinicalTrials.gov (NCT01301911) Study of Cipatinib in Patients With HER2 Positive or Uncertain Advanced Breast Cancer. U.S. National Institutes of Health.

REF 94

ClinicalTrials.gov (NCT03638167) EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors

REF 95

Anti-Tumor Effects of Peptide Therapeutic and Peptide Vaccine Antibody Co-targeting HER-1 and HER-2 in Esophageal Cancer (EC) and HER-1 and IGF-1R in Triple-Negative Breast Cancer (TNBC). Vaccines (Basel). 2015 Jul 6;3(3):519-43.

REF 96

ClinicalTrials.gov (NCT01963715) A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors. U.S. National Institutes of Health.

REF 97

ClinicalTrials.gov (NCT02221882) A Study of LY3164530 in Participants With Cancer

REF 98

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035447)

REF 99

ClinicalTrials.gov (NCT01009866) Study of Immunotoxin, MR1-1. U.S. National Institutes of Health.

REF 100

ClinicalTrials.gov (NCT02537002) Single Dose Study of PF-05230907 in Healthy Japanese Subjects.

REF 101

REF 102

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800013689)

REF 103

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029052)

REF 104

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024847)

REF 105

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005268)

REF 106

REF 107

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019257)

REF 108

A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive br... Nucl Med Biol. 2015 Dec;42(12):931-8.

REF 109

Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. J Nucl Med. 2006 Jun;47(6):1023-31.

REF 110

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026610)

REF 111

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018392)

REF 112

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004971)

REF 113

The heparin-binding domain of heparin-binding EGF-like growth factor can target Pseudomonas exotoxin to kill cells exclusively through heparan sulfate proteoglycans. J Cell Sci. 1994 Sep;107 ( Pt 9):2599-608.

REF 114

Heparin-binding epidermal growth factor-like growth factor is an autocrine growth factor for human keratinocytes. J Biol Chem. 1994 Aug 5;269(31):20060-6.

REF 115

Boehringer Ingelheim. Product Development Pipeline. June 2 2009.

REF 116

Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol. 2002 Oct;29(5 Suppl 14):31-7.

REF 117

Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin Oncol. 2002 Feb;29(1 Suppl 4):27-36.

REF 118

REF 119

Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48.

REF 120

Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.

REF 121

Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC). Semin Cancer Biol. 2004 Feb;14(1):33-40.

REF 122

Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.

REF 123

Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.

REF 124

Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther. 2010 Dec;12(6):741-54.

REF 125

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61.

REF 126

Integration of panitumumab into the treatment of colorectal cancer. Crit Rev Oncol Hematol. 2010 Apr;74(1):16-26.

REF 127

Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76.

REF 128

A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.

REF 129

Clinical pipeline report, company report or official report of AstraZeneca (2009).

REF 130

Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer. 2011 Aug;73(2):195-202.

REF 131

Clinical pipeline report, company report or official report of Roche (2009).

REF 132

Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30;372(18):1700-9.

REF 133

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013 Dec;3(12):1404-15.

REF 134

Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48.

REF 135

Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia. 2013 Oct;15(10):1196-206.

REF 136

Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51.

REF 137

Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.

REF 138

Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Mar Drugs. 2014 January; 12(1): 255-278.

REF 139

Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002 Mar 1;94(5):1593-611.

REF 140

Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC, Journal of Clinical Oncology, Vol 33, No 15_suppl (May 20 Supplement), 2015: 8083.

REF 141

Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93.

REF 142

Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models. Int J Cancer. 2012 May 15;130(10):2445-54.

REF 143

Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell. 2008 Apr;13(4):365-73.

REF 144

Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.

REF 145

Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).

REF 146

EGFR tyrosine kinase inhibitor pelitinib regulates radiation-induced p65-dependent telomerase activation in squamous cell carcinoma.Radiat Res.2013 Mar;179(3):304-12.

REF 147

BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009.

REF 148

AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. Mol Cancer Ther. 2015 Jul;14(7):1614-24.

REF 149

Company report (Biooncology)

REF 150

AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One. 2011;6(7):e21487.

REF 151

Development and validation of a sensitive LC-MS/MS assay for the simultaneous quantification of allitinib and its two metabolites in human plasma.J Pharm Biomed Anal.2013 Dec;86:49-55.

REF 152

Metabolism and pharmacokinetics of allitinib in cancer patients: the roles of cytochrome P450s and epoxide hydrolase in its biotransformation.Drug Metab Dispos.2014 May;42(5):872-84.

REF 153

Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer. 2002 May;38(8):1072-80.

REF 154

World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA. MAbs. 2014 January 1; 6(1): 18-29.

REF 155

A Phase I Study of Immunotoxin, MR1-1. Duke University report.

REF 156

Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)

REF 157

Epidermal growth factor receptor inhibitor PKI-166 governs cardiovascular protection without beneficial effects on the kidney in hypertensive 5/6 nephrectomized rats.J Pharmacol Exp Ther.2013 Jun;345(3):393-403.

REF 158

GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res. 2013 Mar 1;19(5):1126-38.

REF 159

EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice.Diabetes.2009 Dec;58(12):2910-9.

REF 160

Clinical pipeline report, company report or official report of Bristol-Myers Squibb.

REF 161

Retinoic acid-induced RB (retinoblastoma) hypophosphorylation enhanced by CGP 52411 (4,5-dianilinophthalimide), an EGF family tyrosine kinase receptor inhibitor. Eur J Cell Biol. 1996 Apr;69(4):327-34.

REF 162

Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem. 1994 Apr 1;37(7):1015-27.

REF 163

Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase acti... J Med Chem. 1996 Feb 16;39(4):918-28.

REF 164

5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line. Eur J Med Chem. 2009 Sep;44(9):3471-9.

REF 165

Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60.

REF 166

Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine... J Med Chem. 1991 Jun;34(6):1896-907.

REF 167

Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81.

REF 168

Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. J Med Chem. 1999 Mar 25;42(6):1018-26.

REF 169

5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.

REF 170

A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).

REF 171

Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors. Eur J Med Chem. 2008 Jul;43(7):1478-88.

REF 172

Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7.

REF 173

Acryloylamino-salicylanilides as EGFR PTK inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):469-72.

REF 174

Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship anal... J Med Chem. 2009 Feb 26;52(4):964-75.

REF 175

Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6.

REF 176

Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem. 1989 Oct;32(10):2344-52.

REF 177

Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as poten... J Med Chem. 1995 Sep 1;38(18):3482-7.

REF 178

A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.

REF 179

Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB... J Med Chem. 2006 Feb 23;49(4):1475-85.

REF 180

Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.

REF 181

Novel antiproliferative agents derived from lavendustin A. J Med Chem. 1994 Nov 25;37(24):4079-84.

REF 182

Effects of hEGF (MG111) on gastric mucosal potential difference in rats. Scand J Gastroenterol Suppl. 1989;162:198-201.

REF 183

Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a n... J Med Chem. 2003 Dec 4;46(25):5546-51.

REF 184

Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinas... J Med Chem. 1996 Apr 26;39(9):1823-35.

REF 185

Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol. 2007 Apr;3(4):229-38.

REF 186

Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP... J Med Chem. 1999 May 20;42(10):1803-15.

REF 187

Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discover... J Med Chem. 2007 May 31;50(11):2605-8.

REF 188

Selected novel anticancer treatments targeting cell signaling proteins. Oncologist. 2001;6(6):517-37.

REF 189

Growth factors and their receptors: new targets for prostate cancer therapy. Urology. 2001 Aug;58(2 Suppl 1):114-22.

REF 190

Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor... J Med Chem. 2005 Feb 24;48(4):1107-31.

REF 191

Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28.

REF 192

Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem. 1996 Jan 5;39(1):267-76.

REF 193

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.

REF 194

Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.

REF 195

The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7.

REF 196

A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004 Sep 15;64(18):6652-9.

REF 197

Abstract 4451: Evaluation of the therapeutic potential of phosphine oxide pyrazole inhibitors in tumors harboring EGFR C797S mutation. doi:10.1158/1538-7445.AM2019-4451.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.

Prof. Yuzong CHEN

Prof. Feng ZHU